Ionis Pharmaceuticals, Inc. (IONS)
Ionis Pharmaceuticals (IONS) Reports Q2 Loss, Tops Revenue Estimates
Ionis Pharmaceuticals (IONS) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.95. This compares to loss of $0.60 per share a year ago.
Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Should You Buy?
Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ionis (IONS) Up 6% on Detailed Data From Angelman Drug Study
Data from an early-stage study shows that treatment with Ionis' (IONS) ION582 helps improve communication, cognition and motor function in patients with Angelman syndrome, a rare nerve disorder.
Ionis Pharmaceuticals, Inc. (IONS) HALOS Study of ION582 in Angelman Syndrome - (Transcript)
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) HALOS Study of ION582 in Angelman Syndrome Conference Call July 22, 2024 8:00 AM ET Company Participants Wade Walke - Senior Vice President of Investor Relations Brett Monia - Chief Executive Officer Holly Kordasiewicz - Senior Vice President, Neurology Elizabeth Jalazo - Assistant Professor of Pediatrics, Division of Genetics & Metabolism, University of North Carolina School of Medicine Becky Crean - Executive Director, Neurology Lynne Bird - Professor of Clinical Pediatrics, University of California, San Diego, Rady Children's Hospital San Diego Eugene Schneider - Executive Vice President, Chief Clinical Development and Operations Officer Conference Call Participants Debjit Chattopadhyay - Guggenheim Securities Denis Reznik - Raymond James David Lebowitz - Citi Amy Li - Jefferies Yanan Zhu - Wells Fargo Securities Jessica Fye - JPMorgan Jay Olson - Oppenheimer Gena Wang - Barclays Paul Matteis - Stifel Andy Chen - Wolfe Research Salveen Richter - Goldman Sachs Yale Jen - Laidlaw & Company Brendan Smith - Yaron Werber Kostas Biliouris - BMO Capital Markets Jason Gerberry - Bank of America Myles Minter - William Blair Operator Good morning and welcome to Ionis' Conference Call to discuss Ionis' HALOS Study Results. As a reminder, this call is being recorded.
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst
Ionis Pharmaceuticals Inc IONS released results Monday from the completed multiple ascending dose (MAD) portion of the Phase 1/2 open-label study of ION582 in people with Angelman syndrome (AS).
Ionis (IONS) Completes Enrolment for Rare Disease Drug Study
Ionis' (IONS) late-stage study is evaluating zilganersen in a rare neurological disorder called Alexander disease. Top-line data from this study is expected by the end of the next year.
FDA Accepts Ionis' (IONS) NDA for Rare Disease Drug Olezarsen
The FDA grants priority review to Ionis' (IONS) filing seeking approval for olezarsen to treat adults with familial chylomicronemia syndrome. A final decision is expected in December 2024.
Ionis Pharmaceuticals (IONS) Soars 6.8%: Is Further Upside Left in the Stock?
Ionis Pharmaceuticals (IONS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Ionis (IONS) Expands Licensing Deal With Otsuka for HAE Drug
Ionis (IONS) out-licenses the rights for its HAE drug to Otsuka in the Asia-Pacific region. The companies signed a similar deal last year granting Otsuka rights to market the drug in Europe.
Ionis: Tough Run For Share Price Belies Multiple Reasons For Optimism
Ionis Pharmaceuticals' Q1 2024 earnings showed a loss of $143m, a larger loss than the $87m in the previous year. The company has a healthy cash balance of $2.2bn and expects revenues of +$575m in 2024, albeit with further heavy losses. Ionis has several upcoming pipeline opportunities, including the potential approval of pelacarsen and label expansions for Wainua and Olezarsen.
Ionis (IONS), Biogen Down on Ending Development of ALS Drug
Ionis (IONS) and Biogen (BIIB) stop developing their experimental ALS drug after a phase I/II study failed to show improvement in patients.
